Merck's Keytruda nabs 2nd biomarker-driven FDA nod, regardless of tumor type. Is $MRK Keytruda starting a new  “tumor-agnostic indication” trend? #cancer #oncology
https://t.co/7X4CuCbHNS https://t.co/S9wu6B0mlF